M₁ muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease: Implications in future therapy

By Fisher Abraham   Pittel Zipora   Haring Rachel   Bar-Ner Nira   Kliger-Spatz Michal   Natan Niva   Egozi Inbal   Sonego Hagar   Marcovitch Itzhak   Brandeis Rachel  

Journal of Molecular Neuroscience, Vol. 20, Iss. 3, 2003-08 ,pp. : 349-356

Humana Press, Inc

Access to resources Recommend Favorite

M1 Muscarinic Agonists Target Major Hallmarks of Alzheimer's Disease -an Update

By  

Current Alzheimer Research, Vol. 4, Iss. 5, 2007-12 ,pp. : 577-580

Bentham Science Publishers

Access to resources Recommend Favorite

Reduced High-Affinity Agonist Binding at the M 1 Muscarinic Receptor in Alzheimer's Disease Brain: Differential Sensitivity to Agonists and Divalent Cations

By Ladner C.J.   Lee J.M.  

Experimental Neurology, Vol. 158, Iss. 2, 1999-08 ,pp. : 451-458

Elsevier

Access to resources Recommend Favorite

Dual binding site acetylcholinesterase inhibitors: Potential new disease-modifying agents for AD

By Monte-Millán María   García-Palomero Esther   Valenzuela Rita   Usán Paola   Austria Celia   Muñoz-Ruiz Pilar   Rubio Laura   Dorronsoro Isabel   Martínez Ana   Medina Miguel  

Journal of Molecular Neuroscience, Vol. 30, Iss. 1-2, 2006-02 ,pp. : 85-87

Humana Press, Inc

Access to resources Recommend Favorite

The search for disease-modifying drugs for neurodegenerative disorders

By Lenzken Silvia C   Racchi Marco   Lucchelli Adele   Govoni Stefano  

Future Neurology, Vol. 1, Iss. 1, 2006-01 ,pp. : 87-96

Future Medicine

Access to resources Recommend Favorite